Full-year sales reached $26.8 billion, driven by robust performance across HIV, oncology, and liver disease portfolios. HIV sales grew 8% year-over-year to $19.6 billion in 2024, exceeding ...
For Q1 2025, BlackLine projects revenue between $166M and $168M and non-GAAP operating margin of 16.5%-17.5%. Full-year 2025 revenue guidance stands at $699M to $705M, reflecting 7%-8% growth.